Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Focus**: Precision neuroscience, specifically targeting receptor-associated proteins related to AMPA receptors, which are crucial in the treatment of epilepsy [2][4] Key Points and Arguments Unique Mechanism of Action - Rapport Therapeutics is developing RAP-219, which targets TARP gamma 8, an auxiliary protein associated with AMPA receptors, selectively expressed in brain regions critical for focal-onset seizures [3][4] - This selectivity allows for a higher therapeutic index compared to traditional anti-seizure medications, which often have low therapeutic indices and significant side effects [4][10] Clinical Data and Efficacy - The company reported a **72% reduction** in long episodes of electrographic seizures and a **78% median reduction** in clinical seizures during their proof of concept study [13] - A **24% seizure freedom rate** was observed from day 1 to day 56 in the trial [14] - The innovative use of the RNS System for continuous monitoring of electrographic activity allowed for a more efficient study design, reducing the required sample size to 30 patients [16][12] Tolerability Profile - RAP-219 demonstrated a favorable tolerability profile with a **10% discontinuation rate**, which is low for focal epilepsy trials [30] - Common adverse events included dizziness and headache, typical of anti-seizure medications, but were generally mild to moderate [30] Phase 3 Study Plans - Two parallel Phase 3 studies are set to begin in Q2 2026, exploring different dosing strategies (0.25 mg and 0.75 mg in one study, 0.75 mg and 1.25 mg in another) [41] - The studies aim to confirm the efficacy seen in Phase 2 and will include a titration schema over 7-9 days [42] Strategic Partnerships and Market Position - A partnership with Tenacia in China was established, providing a **$20 million upfront payment** and potential for **$308 million in biobucks** and royalties, which will support development in the region [53] - The partnership allows for patient recruitment in China, which has historically been inaccessible for such trials [52] Future Indications and Pipeline - The company plans to expand RAP-219's indications to include primary generalized tonic-clonic seizures and is also exploring its use in bipolar mania, with data expected in 2027 [111][112] - The long-acting injectable (LAI) formulation of RAP-219 is in development, with potential human PK results expected in 2027, which could transform treatment options for epilepsy patients [93][94] Financial Outlook - Rapport Therapeutics has sufficient cash runway into the second half of 2029, allowing for the completion of ongoing studies and the initiation of new trials [121] Additional Important Insights - The company believes that the unique mechanism and efficacy of RAP-219 could position it as a best-in-class therapy for focal-onset seizures [81][88] - The potential for a long-acting injectable formulation could address significant patient needs and extend the revenue durability of the product [96][100] This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Rapport Therapeutics in the epilepsy treatment landscape and its strategic plans for future growth and development.

Core Insights - Firefly Neuroscience, Inc. is collaborating with Heidelberg University Hospital to study the neurophysiological impact of 15q13.3 copy number variants (CNVs) [1][3] - The study utilizes Firefly's FDA-cleared technology to analyze EEG data from 30 subjects, aiming to uncover insights into brain function related to rare genetic conditions [2][3] - The collaboration reflects a commitment to advancing precision neuroscience and aims to bridge the gap between genotype and phenotype for better patient care [3] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, with a proprietary technology called Brain Network Analytics (BNA™) [7][8] - The company has built a comprehensive database of brain wave tests over the past 15 years and has achieved FDA clearance for its technology [7][8] - Firefly is targeting pharmaceutical companies and medical practitioners for the commercial launch of its BNA™ technology [7] Study Objectives - The study aims to identify electrophysiological biomarkers associated with 15q13.3 CNVs [6] - It will characterize neurocognitive profiles linked to deletions versus duplications of the chromosomal region [6] - The research supports future diagnostic and therapeutic strategies for neurodevelopmental disorders [6]

Rapport Therapeutics (RAPP) Conference Summary Company Overview - **Company**: Rapport Therapeutics - **CEO**: Abe Sisan, with over 20 years in the biotech sector, previously president of Cerevel Therapeutics [doc id='4'][doc id='5'] - **CFO**: Troy Nelzi, with extensive experience in finance and business development, raised approximately $5 billion for eight approved products [doc id='3'] Industry Focus - **Sector**: Biotech, specifically in neuroscience and anti-seizure medications - **Key Product**: RAP two one nine (RAP-219), a TARP gamma eight AMPA modulator targeting focal epilepsy [doc id='7'][doc id='10'] Core Scientific Insights - **Receptor Associated Proteins (RAPs)**: Critical for regulating receptor function and signal transduction, allowing for targeted modulation of AMPA receptors [doc id='6'][doc id='8'] - **Differentiation**: RAP-219 aims to achieve significant seizure suppression without common adverse effects like sedation or motor impairment, presenting a potentially unprecedented therapeutic index [doc id='10][doc id='11'] Clinical Development - **Preclinical Evidence**: High probability of success in translating preclinical findings to clinical efficacy in epilepsy, with RAP-219 showing significant efficacy across various models [doc id='12'] - **Phase 2a Trial**: Utilizing an RNS device for objective measurement of efficacy, focusing on long episodes as a biomarker for seizure activity [doc id='15][doc id='16'] - **Expected Outcomes**: Aiming for a 30% reduction in long episodes correlating with at least a 50% reduction in clinical seizures, with results expected in Q3 2025 [doc id='31][doc id='34] Community Engagement and Feedback - **Interest from KOLs**: Significant interest in the trial design and methodology, viewed as a step forward in drug development for epilepsy [doc id='26][doc id='27'] - **Data Presentation**: Recent presentations at the American Academy of Neurology meeting highlighted the predictive value of long episode reductions for clinical seizure outcomes [doc id='28][doc id='29] Future Directions - **Next Steps**: If data is positive, plans to move into parallel Phase 2b/3 registrational trials [doc id='35] - **Pipeline Expansion**: Plans to initiate studies for bipolar mania and neuropathic pain, with data expected in early 2027 for bipolar mania [doc id='40] Conclusion - Rapport Therapeutics is positioned to potentially transform the treatment landscape for epilepsy and other neurological conditions through its innovative approach to drug development and its focus on precision neuroscience [doc id='39]